Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
161 Oyster Point Blvd., South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.46K % +333%
Debt-to-equity 10.1 % -77.7%
Return On Equity -11.5 % +71.4%
Return On Assets -10.4 % +62.2%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 143M shares +4.18%
Common Stock, Shares, Outstanding 143M shares +4.22%
Entity Public Float 2B USD +33.3%
Common Stock, Value, Issued 1.71M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 149M shares +9.43%
Weighted Average Number of Shares Outstanding, Diluted 149M shares +9.43%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 295M USD +201%
Research and Development Expense 402M USD +0.16%
General and Administrative Expense 101M USD +6.71%
Operating Income (Loss) -194M USD +51%
Nonoperating Income (Expense) 51.5M USD +249%
Income Tax Expense (Benefit) 30K USD +42.9%
Net Income (Loss) Attributable to Parent -137M USD +63%
Earnings Per Share, Basic -0.94 USD/shares +67.2%
Earnings Per Share, Diluted -0.94 USD/shares +67.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.6M USD -11.1%
Marketable Securities, Current 876M USD -28.2%
Assets, Current 974M USD -26.5%
Property, Plant and Equipment, Net 46.9M USD +11.3%
Operating Lease, Right-of-Use Asset 25.3M USD -9.77%
Other Assets, Noncurrent 44.6M USD +218%
Assets 1.58B USD +12.2%
Accounts Payable, Current 11.9M USD
Employee-related Liabilities, Current 8.05M USD +9.34%
Accrued Liabilities, Current 5.99M USD
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 82.6M USD -78.9%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 43M USD -14.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 126M USD -71.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.3M USD +48.5%
Retained Earnings (Accumulated Deficit) -1.22B USD -12.7%
Stockholders' Equity Attributable to Parent 1.46B USD +50.6%
Liabilities and Equity 1.58B USD +12.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -114M USD -93.2%
Net Cash Provided by (Used in) Financing Activities 500M USD +31089%
Net Cash Provided by (Used in) Investing Activities -453M USD -389%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 143M shares +4.22%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -66.5M USD +55.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.1M USD -10.7%
Deferred Tax Assets, Valuation Allowance 376M USD +13%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 388M USD +11.6%
Operating Lease, Liability 50.5M USD -11.5%
Payments to Acquire Property, Plant, and Equipment 2.15M USD -22.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -136M USD +62.6%
Lessee, Operating Lease, Liability, to be Paid 62.6M USD -15.1%
Property, Plant and Equipment, Gross 91.6M USD +12.7%
Operating Lease, Liability, Current 7.51M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.8M USD +3.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +3.3%
Deferred Tax Assets, Operating Loss Carryforwards 89.3M USD +32.3%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 30K USD +42.9%
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 26.2M USD +35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 13M USD +3.31%
Operating Lease, Payments 11.1M USD -3.67%
Additional Paid in Capital 2.67B USD +30.5%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD -100%
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 2.16M USD -78.5%
Deferred Tax Assets, Net of Valuation Allowance 12M USD -18.7%
Share-based Payment Arrangement, Expense 108M USD +5.97%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%